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Background. Thoracic aortic aneurysm (TAA) is usually asymptomatic and associated with high mortality. Adverse clinical
outcome of TAA is preventable by elective surgical repair; however, identifying at-risk individuals is difficult. We hypothesized
that gene expression patterns in peripheral blood cells may correlate with TAA disease status. Our goal was to identify
a distinct gene expression signature in peripheral blood that may identify individuals at risk for TAA. Methods and Findings.
Whole genome gene expression profiles from 94 peripheral blood samples (collected from 58 individuals with TAA and 36
controls) were analyzed. Significance Analysis of Microarray (SAM) identified potential signature genes characterizing TAA vs.
normal, ascending vs. descending TAA, and sporadic vs. familial TAA. Using a training set containing 36 TAA patients and 25
controls, a 41-gene classification model was constructed for detecting TAA status and an overall accuracy of 7866% was
achieved. Testing this classifier on an independent validation set containing 22 TAA samples and 11 controls yielded an overall
classification accuracy of 78%. These 41 classifier genes were further validated by TaqManH real-time PCR assays. Classification
based on the TaqManH data replicated the microarray results and achieved 80% classification accuracy on the testing set.
Conclusions. This study identified informative gene expression signatures in peripheral blood cells that can characterize TAA
status and subtypes of TAA. Moreover, a 41-gene classifier based on expression signature can identify TAA patients with high
accuracy. The transcriptional programs in peripheral blood leading to the identification of these markers also provide insights
into the mechanism of development of aortic aneurysms and highlight potential targets for therapeutic intervention. The
classifier genes identified in this study, and validated by TaqManH real-time PCR, define a set of promising potential diagnostic
markers, setting the stage for a blood-based gene expression test to facilitate early detection of TAA.
Citation: Wang Y, Barbacioru CC, Shiffman D, Balasubramanian S, Iakoubova O, et al (2007) Gene Expression Signature in Peripheral Blood Detects
Thoracic Aortic Aneurysm. PLoS ONE 2(10): e1050. doi:10.1371/journal.pone.0001050
INTRODUCTION
Thoracic aortic aneurysm (TAA), without surgical treatment, is
a lethal disease [1,2]; yet, with elective surgical treatment, a near-
normal prognosis is restored. Thus, in aneurysm disease, early
diagnosis is the key to survival via timely elective surgery. Because
TAA is almost invariably asymptomatic until rupture or dissection
occurs, detection methods must be applied to asymptomatic
individuals. Physical examinations generally do not detect TAA,
thus imaging technologies such as echocardiography (ECHO),
computerized tomography (CT), or magnetic resonance imaging
(MRI) are used for diagnosis of this disease. Although radiographic
screening is extremely valuable, many patients who have an
increased genetic risk of developing aneurysms later in life may not
have recognizable enlargement of the aorta at the time of
screening, even with state-of-the-art imaging technologies. Thus
a standardized blood-based test capable of detecting individuals at
risk for aneurysm disease would represent a major advance in
clinical care.
Circulating leukocytes serve as a vigilant and comprehensive
surveillance system that patrols the body for signs of infection,
inflammation, and structural abnormalities. Therefore, a disease-
specific gene expression signature in peripheral blood cells (PBCs)
could constitute potential disease markers as well as genes involved
in pathogenesis of the disease. PBCs have been used to identify
gene expression signatures for autoimmune diseases such as
systemic lupus erythematosus (SLE) [3,4], rheumatoid arthritis
(RA) [5], and multiple sclerosis (MS) [3,6,7]. These signatures
genes have been also shown to be useful in identifying pathways
relevant to disease[8] and in predicting response to therapy [9].
Recent studies have also provided evidence that blood cell gene
expression profiling might have utility in the detection of complex
cardiovascular diseases such as atherosclerosis [10], coronary
artery disease [11,12], and arterial hypertension [13].
Due to the difficulty in obtaining diseased aortic tissue and
functional complexity of the system, the mechanisms responsible
for the formation of TAA remain elusive; however, the importance
of genetic predisposition [14–17], inflammation [18–21], and
adaptive cellular immune responses [22–24] in the development of
aneurysm disease have been well appreciated. In addition,
circulating blood cells are in close contact with the diseased aortic
tissue and, therefore, may well serve as reporters for potential
disease markers for TAA. For these reasons, it seems likely that
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PLoS ONE | www.plosone.org 1 October 2007 | Issue 10 | e1050gene expression patterns in peripheral blood cells may reflect TAA
disease status. In this study, we compared gene expression profiles
in peripheral blood cells of individuals with asymptomatic TAA to
those of carefully-chosen controls and asked if we can identify
a gene expression based TAA-status classifier that can distinguish
between individuals with asymptomatic TAA and those without
disease.
METHODS
The study was approved by the Yale University Human
Investigation Committee (Protocol #12617). All patients gave
advance written approval for inclusion in the study.
Blood samples collection
Peripheral blood was harvested from 58 TAA patients and 36
spousal controls using PAXgene
TM tubes (Qiagen, Valencia, CA).
All patients (39 male, 19 female) harbored known thoracic aortic
aneurysms, based on radiographic images (ECHO, CT, or MRI)
and/or operative findings. Since this study focuses on thoracic
aortic aneurysms without known underlying disorders, patients
with Marfan syndrome were specifically excluded. Spousal
controls were chosen because of the similarities in age, ethnicity,
geography, and diet that usually characterize husband and wife.
Complete blood counts of all blood samples were carried out at the
Clinical Laboratory of Yale-New Haven Hospital.
RNA preparation
The PAXgene
TM tubes were frozen at the collection site and
shipped on dry ice. After thawing at room temperature for at least
2 hours, total RNA was extracted from the approximately 2.5 ml
of peripheral blood in each tube following the manufacturer’s
recommended protocol (Preanalytix Blood RNA Kit Handbook,
Qiagen). The quality and integrity of the total RNA was evaluated
on the 2100 Bioanalyzer (Agilent Technologies) and the
concentration was measured using a NanoDrop spectrophotom-
eter (NanoDrop Technologies). Globin reduction step was not
performed based on the observation that the typical detection rates
are similar (55–60% with threshold of S/N.3) between RNA
samples directly purified from PAXgene tubes and RNA samples
purified from peripheral blood mononuclear cells (PBMC) (data
not shown).
Applied Biosystems Expression Array analysis The
Applied Biosystems Human Genome Survey Microarray v2.0
(P/N 4337467) contains 33,096 60-mer oligonucleotide probes
representing 29,098 individual human genes. cRNA labeling,
hybridization and detection were carried out as described
previously [25]. For inter-array normalization, we applied
Quantile normalization across all microarrays to achieve the
same distribution of signal intensities for each array.
SAM Significance analysis of microarrays (SAM; available at
http://www-stat.stanford.edu/tibs/SAM/) [26] was used to
determine potential signature genes that could distinguish TAA
from control samples, or distinguish ascending TAA from
descending TAA samples.
Hierarchical clustering analysis Average-linkage hier-
archical clustering analysis using centered correlation analysis
and visualization was performed using the CLUSTER and
TREEVIEW programs (software available at http://genome-
www5.stanford.edu/resources/restech.shtml).
PANTHER
TM Protein Classification System analy-
sis PANTHER
TM (Protein ANalysis THrough Evolutionary
Relationships) Protein Classification System (Applied Biosystems,
Foster City, CA https://panther.appliedbiosystems.com) classifies
proteins in families/sub-families, molecular functions, biological
processes and biological pathways [27]. Molecular functions,
biological processes and biological pathways over-represented by
‘‘signature’’ genes of the TAA were identified and the statistical
significance of the over-representation was quantified by a random
overlapping p value using the binomial test with all the genes
represented by the Applied Biosystems Human Genome Survey
Microarray as the reference list [28]. Bonferroni correction for
multiple testing was also applied to p values used for determining
significance in molecular function and biological process.
Construction and validation of classification models
for TAA detection
A 61-sample training set containing 36 TAA patients (24 males
and 12 females) and 25 controls (7 males, 18 females) were used to
select classifier genes and construct a classification model. Genes
were first selected based on the criteria that their expression levels
are above the detection threshold (Signal to Noise.3) in$50% of
samples in either TAA or control group. The resulting 16,656
genes from the filtering were then subjected to further gene
selection. The classification power for each gene was evaluated
using the bootstrap re-sampling method [29] coupled with two-
tailed t-statistics. Specifically, during each bootstrap re-sampling
process, equal numbers (n=25) of TAA and control samples were
partitioned (repetition allowed) to form a new data set. A two-
tailed t-statistic was applied to the new data set and the top 500
genes with the most significant p-value were selected. This
bootstrap re-sampling process was repeated for 500 times and
a total of five hundred 500-gene lists were generated. Genes were
then ranked based on their frequency in the 500 500-gene lists and
genes with frequency.50% and with average ranking.500 were
chosen for further analysis (in general about 105–120 genes). Class
prediction was performed by using prediction analysis of
microarrays (PAM), a statistical package (http://www-stat.stan-
ford.edu/,tibs/PAM/) that applies nearest shrunken centroid
analysis for sample classification [30]. The optimal number of
classifier genes was determined using 10-fold cross validation
method on the training set. The 61 (training) samples are
partitioned into 10 bins, with equal representation of TAA and
controls as the initial set of samples. Nine bins are used for learning
purposes to generate an ordered gene list (as described above)
based on the gene’s probability to be ranked in top 500 most
discriminative genes. For any set of top 1, 2, 3, …n genes of this
ordered list of genes, classification models were built using the 9
(learning) bins and the TAA status of samples belonging to the
remaining bin was classified. Using clinical diagnostics as the
reference, true positives (TP), true negative (TN), false positive
(FP), and false negative (FN) were calculated. The classification
performance was evaluated using the following statistics:
Sensitivity~
TP
TPzFN
Specificity~
TN
FPzTN
Accuracy~
TPzTN
TPzFPzTNzFN
TaqManH real-time PCR assay validation
Out of 94 samples analyzed by microarrays, only 82 samples (52
training samples, 30 testing samples) had enough RNA materials
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expression of 71 genes was measured in each of the 82 samples by
real-time PCR using TaqManH Gene Expression Assays and the
7900HT Fast Real-Time PCR System (Applied Biosystems, Foster
City, CA). cDNAs were generated from 30 ng of total RNA using
the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA). The resulting cDNA was subjected
to a 14-cycle PCR amplification followed by real-time PCR
reaction using the manufacturer’s TaqManH PreAmp Master Mix
Kit Protocol (Applied Biosystems, PN 4366127). Four replicates
were run for each gene for each sample in a 384-well format plate.
Between the two measured endogenous control genes (PPIA (Alias:
cyclophilin A) and MGB2), we chose PPIA for normalization
across different genes based on the fact that this gene showed the
most relatively constant expression in different breast carcinomas
(data not shown). Based on TaqMan assay data, the coefficients of
the 41 classifier genes were re-learned from the 52 training
samples and used to classify the 30 testing samples using the same
method applied to microarray data.
GEO accession The complete data sets of this study
including both microarray and TaqManH assay data can be
accessed from GEO with accession number GSE9106. (http://
www.ncbi.nlm.nih.gov/projects/geo/)
RESULTS
Gene expression signature of TAA in PBCs
PBCs from 58 TAA patients and 36 spousal controls were
analyzed in this study. The clinical and demographic character-
istics of patients and controls are summarized in Table 1. All
subjects of this study are Caucasians. Complete blood cell counts,
including white blood cell (WBC), neutrophils, lymphocytes,
monocytes, eosinophils and basophils, were determined in all
blood samples collected from TAA patients and controls. None of
these specific cell counts demonstrated significant association with
the TAA disease status based on logistic regression analysis (data
not shown).
To explore whether we can identify a gene expression signature
of TAA disease from peripheral blood samples, gene expression
profiles of 61 whole-blood RNA samples (training set) collected
from 36 TAA patients and 25 controls were analyzed using the
Applied Biosystems Human Genome Survey Microarrays repre-
senting 29,098 individual human genes. Using SAM analysis, 1207
genes were differentially expressed between the TAA and control
groups based on the following criteria: (1) false discovery rate
(FDR),4% from 300 permutation testing; and (2) average fold
change between the TAA patients and controls.1.3-fold. To
examine whether the imbalanced gender distribution within the
TAA and control groups (Table 1) may confound the identification
of TAA signature genes, SAM analysis was performed between the
31 male and 30 female samples within the training set. Twenty-
eight genes were identified as gender-specific genes using the same
criteria (FDR,4% and.1.3-fold between the two gender groups).
Not surprisingly, 21 out of the 28 gender-specific genes were found
located on either Y or X chromosome. Eight of the 28 gender
specific genes (5 Y-linked and 3-X linked) were also found in the
list of 1207 differentially expressed genes and were excluded from
further analysis. Figure 1A displays hierarchical clustering
diagrams of the 61 training set samples using the remaining
1199 potential TAA signature genes, among which, 988 genes
were over-expressed and 211 genes were under-expressed in TAA
patients when compared to the control samples (Figure 1A,
complete gene list is listed in Table S1). These signature genes
generally clustered the TAA patients and the controls into two
distinct branches with only a few exceptions (Figure 1B).
PANTHER
TM Protein Classification System analysis[27]
showed that after correction for multiple hypothesis testing there
were statistically significant enrichments of transcripts within the
988 genes that are up-regulated in the TAA patients, displaying
interleukin signaling (p-value=0.01), the fibroblast growth factor
(FGF) signaling (p-value=0.05), and the endothelin signaling
activities (p-value=0.05) (Figure 1C). The over-expressed genes
included the Th2-derived cytokine IL-10 and other genes involved
in the downstream JAK/STAT signaling cascade, including
tyrosine kinase JAK3, map kinases (MAPK6, MAPK7) and signal
transducer and activator of transcription STAT2, suggesting
a coordinated Th2-activated immune response associated with
the circulating cells of the TAA patients. On the other hand,
statistically significant association of the 211 down-regulated genes
in TAA patients was observed with pathways such as T-cell
activation (p-value=4E-15), Fas-mediated apoptosis (p-val-
ue=0.03), and Wnt signaling (p-value=0.04) (Figure 1C).
Construction of classification model for detection of
TAA
Our goal was to identify a distinct gene expression signature in
peripheral blood that may allow development of noninvasive
screening tests to identify individuals at risk for TAA disease. Due
to the high inter-individual variability, we applied a bootstrapping
strategy [29] that takes into account of the complex relationship
between genes, as well as the variability between samples. Such
a strategy minimizes the impact of extreme outlier samples and
allows confidence estimations for classifier gene selection. Classifier
gene selection was done by evaluating each gene using a bootstrap
re-sampling method coupled with two-tailed t-statistics (described
in the Methods). The discriminative power of each gene was
ranked during each bootstrap re-sampling process and this
bootstrap re-sampling process was repeated for 500 times. The
most discriminative genes (,100) were identified using the
following criteria: (1) with.50% frequency in appearing in the
top 500 ranks among the 500 bootstrap re-sampling; (2) with
average rank,500. To determine an optimal number of classifier
genes, we started from the selected 100 genes and removed one
gene at a time and estimated the corresponding classification
accuracy using a 10-fold cross-validation on the training set [30].
A 41-gene classifier was identified based on its consistency in
classification accuracy (Figure S1). 10-fold cross-validation of the
41-gene model on the training set yielded an overall classification
accuracy (average 7866%), sensitivity (average 8166%) and
specificity (average 7566%)(Figure 2A). Principal component
Table 1. Summary of clinical characteristics of 94 TAA patients
and controls.
......................................................................
Training set (n=61 ) Testing set ( n=33 )
TAA Control TAA Control
Individual 36 25 22 11
Male|Female 24|12 7|18 15|7 5|6
Median age (range) 71 (41–88) 63 (44–87) 62 (32–82) 66 (52–86)
Average size 5.3 cm NA 5.0 cm NA
Location (Asc|Dsc|Other) 31|5|0 NA 16|4|2 NA
Smoker 11 4 9 4
Familial 7N A5N A
doi:10.1371/journal.pone.0001050.t001
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PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e1050Figure 1. Hierarchical clustering of 61 whole blood samples analyzed by Applied Biosystem Expression Arrays using the 1199 differentially
expressed genes determined by SAM analysis. The level of expression of each gene in each sample, relative to the mean level of expression of that
gene across all the samples, is represented using a red-black-green color scale as shown in the key (green: below mean; black: equal to mean; red:
above mean). (A). Scaled down representation of the entire cluster of the 1199 signature genes and 61 whole blood samples. (B). Experimental
dendrogram displaying the clustering of the samples into two main branches: the TAA branch (red) and the control branch (blue) with a few
exceptions. (C). Gene expression pattern of representative genes within biological pathways that are statistically significantly over-represented
(random overlapping p-value,0.05) by the up-regulated (red bars) or the down-regulated (blue bars) signature genes of TAA.
doi:10.1371/journal.pone.0001050.g001
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PLoS ONE | www.plosone.org 4 October 2007 | Issue 10 | e1050analysis using the 41 classifier genes can segregate TAA samples
from control samples in three dimensional spaces with only a few
exceptions (Figure 2B). The list of the 41 classifier genes is
presented in Table 2.
As an independent measure of the validity of the 41-gene
classification model, we tested an independent cohort consisting of
33 peripheral blood samples (22 TAA and 11 controls), more than
half of which were collected at least one year after the completion
of the first set. RNAs extracted from these samples were analyzed
using Applied Biosystems Human Genome Arrays using the same
protocols as the training set, but by different operators and
instruments. The classification accuracy, sensitivity, and specificity
for the testing set were 78%, 72%, and 90% respectively (Figure 3),
consistent with the results estimated by the 10-fold cross validation
on the training set (Figure 2A).
TaqManH real-time PCR assay validation
To further validate the TAA-status classifier genes, we determined
expression levels of the 41 TAA-status classifier genes using the
more precise real-time PCR methodology on 82 samples for which
enough RNA was available (50 samples from training set and 32
samples from test set). Similar classification performance was
achieved using real-time PCR data compared to that of
microarray data: the classification accuracy, sensitivity and
specificity for the testing set based on TaqManH assay data were
80%, 71%, and 100% respectively (Figure 4).
Molecular profiles characterizing subtypes of TAA
One of the main clinical characteristics of TAA is the location of
the aneurysm (i.e. in ascending vs. descending aorta). Aneurysms
in these two locations tend to represent very different clinical
phenomena [31]. The location of an aneurysm is distinctly
connected with the embryology, pathogenesis, clinical course, and
treatment of a thoracic aneurysm.
To explore whether we can identify signature expression profiles
characterizing location-specific TAA, SAM analysis was per-
formed on 36 TAA samples within the training set (31 ascending
vs. 5 descending). One hundred and forty-four genes were
significantly over-expressed in the ascending TAA samples
(FDR,2%, FC.1.3) (Table S2). Hierarchical clustering analysis
of these 144 genes grouped the descending and ascending TAA
samples into two distinct and separate clusters (Figure 5A).
PANTHER
TM Protein Classification System analysis revealed that
genes involved in cell cycle regulation (i.e. RAD21, ORC2,
LRPA1, MCM3, FOXO1A, and CCNG1) are significantly over-
represented in the set of 144 genes that are differentially expressed
in samples from patients with ascending TAA (p-value=3.4E-3).
This set also contained thirteen transcription factors (p-value=
0.02, Figure 5A), including ELF1 and ELF2, two transcription
factors involved in the platelet derived growth factor (PDGF)
signaling pathway , which plays a critical role in cellular
proliferation and development.
Familial aggregation studies indicate that up to 20% of patients
with TAA (who do not have Marfan syndrome) have a first-degree
relative with the disease[1,31–33]. To investigate potential gene
expression signatures characterizing familial and sporadic TAA,
we performed SAM analysis on 7 TAA patients with a family
history of the disease and 27 TAA patients without a family history
of the disease (sporadic), all from within the training set. One
hundred and thirteen genes were identified as significantly up-
regulated in patients with sporadic TAA (average FC.1.3 and
FDR,4%) and hierarchical clustering based on these genes
clustered the familial and sporadic TAA patients into distinct
branches (Figure 5B) (Table S3). PANTHER
TM Protein Classifi-
cation System analysis revealed that this set of genes up-regulated
in patients with sporadic TAA was statistically enriched for genes
involved in various aspects of DNA metabolism (p-value=1.1E-6),
including DNA replication (LOC150580, MCM5, TNKS2), DNA
repair (ERCC5, CSNK1A1L) and DNA recombination
Figure 2. A set of 41 classifier genes were identified via 10-fold cross-validation on the 61-sample training set. (A). Classification accuracy,
sensitivity and specificity of the 41 classifier genes, error bar represents61 standard deviation among 100 times of independent 10-fold cross-
validation process; (B). 3D Plots of the first three principal components based on PCA analysis. The segregation between TAA and control samples is
evident with only a few exceptions.
doi:10.1371/journal.pone.0001050.g002
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PLoS ONE | www.plosone.org 5 October 2007 | Issue 10 | e1050(SWAP70). Several genes involved in glycolysis (PGAM1 and GPI)
and interferon signaling (PIAS1,PIAS2) were also significantly up-
regulated within the sporadic TAA peripheral blood. Another
interesting gene specifically down-regulated in familial TAA is the
angiogenic factor AGGF1. This gene, located at chromosome
5q13.3, is within the previously mapped 5q13–14 locus associated
with familial TAA [14,34].
Twenty eight signature genes characterizing sub-types of TAA
were also validated by TaqMan real time PCR assays. Even
though the average fold changes for most of these signature genes
are relatively small (mostly,2-fold), these were reproducible, as
shown by 89% concordance between the TaqMan assay data and
the microarray data (Table S4).
Finally, SAM analysis was also performed to identify signature
genes correlated with age, aneurysm size and smoking status of
TAA patients; however, no genes were found to correlate
significantly with these factors (data not shown).
DISCUSSION
It has become increasingly evident that the immune system plays
a pivotal role in the development of aortic aneurysms [18–24]. We
thus hypothesized that gene expression patterns in peripheral blood
cells may reflect TAA disease status. The specific aim of this study
was to obtain a distinct molecular signature that can signal the
presence of TAA and potentially identify at-risk patients for further
clinical and radiological testing. Through a whole-genome gene
expression profiling analysis in a relatively large number of thoracic
aneurysm patients and controls, we have identified a 41-gene
signature in peripheral blood cells that distinguishes TAA patients
fromcontrols.Thissetof41classifiergenes,derivedfrommicroarray
analysis and further validated by TaqManH real-time PCR assays,
detects TAA disease with an overall classification accuracy of 78–
80%, which is a promising level for potential clinical applications.
Moreover, this investigation also provided a comprehensive
analysis of the gene expression programs that characterize the
peripheral blood cells of TAA patients,whichmayreflectactivities of
the immune cells at the site of the disease. It is encouraging,
therefore, that manyof the biologicalpathways (and genes) identified
in this study, such as interleukin signaling, T-cell activation and
apoptosis, have been associated with development of aneurysm
diseases [18,23,24,35]. For example, the interleukin signaling
pathway has been particularly well studied in the aneurismal context
[18–21,36,37]. Both pro- and anti-inflammatory cytokines have
been postulated to play vital roles in development, rupture and
repair of aneurysms [36,37]. These include interferon-gamma (IFN-
gamma), interleukin-6 (IL-6), and interleukin-10 (IL-10). It is
interesting that the major pro-inflammatory cytokines IL-6 and
IFN-gamma did not appear among the significantly differentially
expressed genes in our study. In contrast, our results revealed an
over-expression of IL-10 in the peripheral blood cells of TAA
patients, as well as a coordinated up-regulation of several
components of the downstream signaling pathways, namely various
members of the JAK/STAT/MAPK families. IL-10 is, like most
interleukins, a pleiotropic cytokine, but is somewhat unusual in that
its actions are primarily anti-inflammatory. It is secreted mainly by
monocytes and the Th2-subset of CD4+ T-cells and is capable of
polarizing the inflammatory response towards a Th2 type; this latter
property might play a role in aneurysm since it has been reported
that a Th2-type inflammation and blockade of the Th1 cytokine
IFN-gamma induce aneurysms in allografted aorta in mice [38].
Over-expression of IL-10 has also been noted in aortic tissue from
abdominal aortic aneurysm (AAA) patients compared to normals or
carotid atheroma patients [24,39]. Thus over-expression of IL-10
could,inthisscenario,inhibittheTh1responseandincreasetheTh2
contribution, leading to the development of aneurysm. However,
there is a large body of evidence to show that a Th1-directed
inflammation and IFN-gamma release activate macrophages to
secreteMMPsandacceleratetheonsetoftissuedegenerationleading
to aneurysm [18,40]. And in fact, IL-10 has indeed been reported to
Table 2. List of the 41 classifier genes that distinguish TAA
from normal individuals.
......................................................................
Array
Probe ID Primary Gene ID
Gene
Symbol
Frequency in top
500 ranks among
500 bootstrap
resampling
Expression
in TAA
124958 56143 PCDHA5 0.82 Up
227481 374897 SBSN 0.82 Up
182618 hCG1773879.2 0.80 Up
219146 348932 SLC6A18 0.77 Up
211834 hCG1820398.1 0.77 Up
214799 219968 OR5B21 0.77 Up
619119 388751 LOC388751 0.76 Up
196612 22875 ENPP4 0.72 Up
213445 8809 IL18R1 0.72 Up
208499 283349 RASSF3 0.71 Up
410937 387695 C10orf99 0.71 Up
163657 8831 SYNGAP1 0.69 Up
183110 hCG2028451.1 0.65 Up
137330 hCG1820722.2 0.64 Up
141979 5998 RGS3 0.64 Up
115931 64100 ELSPBP1 0.63 Up
214599 29957 SLC25A24 0.60 Up
192269 6944 VPS72 0.96 Down
117989 3615 IMPDH2 0.93 Down
139001 3033 HADHSC 0.92 Down
206569 6631 SNRPC 0.88 Down
156536 5245 PHB 0.88 Down
125597 79001 VKORC1 0.87 Down
179149 3163 HMOX2 0.82 Down
179328 8607 RUVBL1 0.82 Down
162516 231 AKR1B1 0.78 Down
201766 6184 RPN1 0.77 Down
115653 8721 EDF1 0.77 Down
185037 1019 CDK4 0.77 Down
178575 128240 APOA1BP 0.75 Down
154562 25764 HYPK 0.71 Down
175040 516 ATP5G1 0.68 Down
187195 29101 SSU72 0.67 Down
119963 10001 MED6 0.66 Down
232086 hCG2042278 0.65 Down
173844 4282 MIF 0.65 Down
180941 hCG1793363.2 0.62 Down
112601 79228 WDR58 0.62 Down
224173 83858 ATAD3B 0.61 Down
204089 51070 NOSIP 0.61 Down
178334 11164 NUDT5 0.59 Down
doi:10.1371/journal.pone.0001050.t002
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PLoS ONE | www.plosone.org 6 October 2007 | Issue 10 | e1050limit the cytotoxic potential of macrophages and to reduce the
expression of pro-inflammatory mediators such as cytokines or
matrix metalloproteinases (MMPs) [41,42]. It is also capable of
driving down the Th1 response, and directly inhibiting IFN-gamma;
thus it is likely that IL-10 over-expression is in fact a beneficial
immune response to counteract the MMP production and limit
injury. This view is in agreement with the reported increase in IL-10
in pre-operative AAA [36] and observations of increased IL-10
Figure 3. Validation of the 41-gene classification model using microarray analysis on an independent set of testing samples. (A). Classification
probabilities for each testing sample: TAA (case) vs. normal (control); (B). Contingency table summarizes the predicted and actual class membership
for the testing set; (C). Classification accuracy, sensitivity and specificity.
doi:10.1371/journal.pone.0001050.g003
Figure 4. Validation of the 41 classifier genes using TaqMan real-time PCR assays. The expression profile of the 41 classifier genes was measured in
each of the 82 samples by real-time PCR using TaqManH Gene Expression Assays. Based on TaqMan assay data, the coefficient of the 41 classifier
genes were re-learned from the 52 training samples and used to classify the status of 30 testing samples using the same method applied to
microarray data. (A). Classification probabilities for each testing sample: TAA (case) vs. normal (control); (B). Contingency table summarizes the
predicted and actual class membership for the testing set; (C). Classification accuracy, sensitivity and specificity.
doi:10.1371/journal.pone.0001050.g004
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PLoS ONE | www.plosone.org 7 October 2007 | Issue 10 | e1050immediately following surgery; in fact, a Phase I clinical trial has
been initiated to examine the benefit of IL-10 administration
following TAA repair surgery [43]. This view of Th1-directed
aneurysmandlaterincreaseofIL-10andTh2-directed responseisin
line with the known anti-inflammatory properties of IL-10, as has
been suggested [44]. Another example of this protective immune
response is the down-regulation of the T-cell activation pathway
observed in this study, primarily occurring by down-regulation of
subunits of the T-cell receptor and its immediate downstream
signaling components. Again, this could be another late mechanism
for modulating the inflammatory stimulus and limiting subsequent
tissue damage.
The observed down-regulation of members of the Fas/apoptosis
pathway such as AKT3 in TAA could also be related to the
reported apoptosis of vascular smooth muscle cells (VSMC), which
might otherwise repair the tissue damage described above [35].
AKT3 is known to regulate Fas sensitivity and promote cell
survival [45]. Down-regulation of Akt signaling may induce Fas
ligand expression and promote Fas-mediated apoptosis in VSMC
[46]. Another interesting finding of this study is the endothelin
pathway, including endothelin-converting enzyme 2 (ECE-2) was
up-regulated in TAA. Endothelins are well known to be potent
vasoconstrictors that play a major role in vasospasms following
cerebral aneurysms [47], and inhibitors of endothelin-converting
enzymes are in development for prevention and treatment of these
conditions. The potential involvement of endothelin-converting
enzymes in the pathogenesis of thoracic aneurysms has not
received much attention, and may merit further study.
While the statistically significant pathways emerging from the
transcriptional analysis may provide mechanistic insights, many of
the individual genes in these pathways are not among those in the
41-gene marker set. As mentioned earlier, this may be because
many of these pathway genes are commonly involved in many
other processes in addition to aneurysms and may not be
sufficiently discriminatory for the particular function of distin-
guishing TAA PBC from normal. However, some of the genes in
the 41-gene classifier list can be related mechanistically to
aneurysm–for example, macrophage migration inhibition factor
(MIF), is released by immune cells, and is a potent stimulator of
Th1 cells, inducing the release of pro-inflammatory cytokines
including IFN-gamma. High levels of MIF have been correlated
with AAA, which is also common in TAA patients following
Figure 5. Two-dimensional cluster diagrams. (A).144 signature genes characterizing the ascending and descending TAA subtypes; (B). 113 signature
genes characterizing the TAA with or without family history. Representative genes associated with over-represented molecular functions/biological
processes/pathways are listed.
doi:10.1371/journal.pone.0001050.g005
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PLoS ONE | www.plosone.org 8 October 2007 | Issue 10 | e1050surgery [48,49]. The observed down-regulation of MIF in PBC
from this study could therefore be a beneficial response.
This investigation also identified distinct gene expression profiles
for subtypes of TAA, including ascending vs. descending TAA and
familial vs. sporadic TAA. It is worth noting that these profiles were
derived from relatively small numbers of samples, therefore they
should be considered as preliminary observations on expression
patternof these subtypesof TAA. The classification gene set needs to
be further established and cross-validated in studies with larger
sample sizes. On the other hand, these results provide further
evidence supporting the current understanding that ascending and
descending thoracic aortic aneurysms may represent two very
different diseases with widely differing, pathophysiology, and clinical
manifestations [50] and, therefore, may need different therapeutic
strategies. It is also consistent with the increasing recognition that
TAA disease is indeed transmitted in an inherited fashion in at least
one-fifth of patients [31] and opens many interesting avenues to
explore in future studies. One particular interesting finding of this
study is the angiogenic factor AGGF1 gene, which was identified as
one of the potential signature genes distinguishing familial vs.
sporadic TAA. AGGF1 is located at chromosome 5q13.3, which is
mapped within the previously mapped 5q13–14 locus that has been
shown to be associated with familial TAA [14,34]. Therefore,
AGGF1shouldbeevaluatedasacandidategeneforTAA.Thus,our
gene expression profiles of PBC may provide additional information
to genetic studies of TAA and help to identify potential disease-
associated genes for familial TAA. Finally, our identification of
a specific signature for sporadic TAA also holds special promise in
general screening of TAA disease, because traditional radiographic
imaging methods or genetic tests that are potentially applicable to
known affected families cannot be applied to sporadic cases due to
the low cost-effectiveness.
There are potential limitations of this study that should be
considered. First, the choice of spouses as controls for this study
may be sub-optimal; however, the advantage of using spousal
controls over randomly chosen normal individuals is that they
share many demographic and environmental factors such as age,
geography, and diet. Secondly, while the TAA signature genes
identified in PBC may provide clues to pathogenic processes of the
disease, any biological pathways underlying these signature genes
need to be further evaluated in mechanistic studies derived from
diseased aortic tissues. It must be reiterated that the strength of this
study lies primarily in the identification of disease markers in
peripheral blood cells, which is a preferred choice for the purpose
of early diagnosis of TAA. Third, it remains to be determined
whether the TAA signature can be applied to detect abdominal
aortic aneurysms (AAA), especially since it has been shown that
patients with descending TAA were likely to have kindred with
AAA [33]. Preliminary analysis showed no significant overlapping
between the TAA signature genes identified in this study and those
reported for other vascular diseases such as atherosclerosis [10],
coronary artery disease[11,12] and arterial hypertension [13],
suggesting that this signature is specific to TAA rather than
a general signature for vascular disease or inflammation. Finally,
although we believe the TAA classifier genes identified in this
study define potential diagnostic markers for TAA, we want to
emphasize that further study needs to be done before clinical
application, including independent validation (retrospective and
prospective) with larger numbers of subjects and determining the
positive prediction value (PPV) and negative prediction value
(NPV) in the context of a clinical diagnostic test.
In conclusion, we have identified informative gene expression
signatures in peripheral blood cells that can distinguish TAA status
andsubtypesofTAA.Fromthesedata,wehaveidentifiedasignature
set of 41 biomarker genes which can identify asymptomatic TAA
patients with high accuracy. This can potentially lead to a diagnostic
‘‘point-of-care’’ assay, for identification of asymptomatic TAA
disease with a simple blood-based test. The transcriptional programs
in peripheral blood leading to the identification of these markers also
provide insights into the mechanism of development of aortic
aneurysms, and highlight potential targets for therapeutic interven-
tion.We are hopeful that the findings of this investigation can lead to
betterandearlierdiagnosisoftheaneurysmdiathesis,thusprotecting
humans from this lethal disease.
SUPPORTING INFORMATION
Figure S1 Determination of the optimal set of classifier genes
using 10-fold cross-validation on the training set (see detailed
description in Methods). Classification accuracy using different
number of classifier genes was illustrated; the error bar
indicates61 SD among 100 times of independent 10-fold cross-
validation process.
Found at: doi:10.1371/journal.pone.0001050.s001 (0.26 MB TIF)
Table S1 1199 significantly differentially expressed genes
distinguishing TAA vs. control, identified based on microarray
data and SAM analysis (ave. FC.1.3 and FDR,4%)
Found at: doi:10.1371/journal.pone.0001050.s002 (0.22 MB
XLS)
Table S2 144 candidate signature genes distinguishing ascend-
ing vs. descending TAA, identified based on microarray data and
SAM analysis (ave. FC.1.3 and FDR,2%)
Found at: doi:10.1371/journal.pone.0001050.s003 (0.04 MB
XLS)
Table S3 113 candidate signature genes distinguishing familial
vs. sporadic TAA, identified based on microarray data and SAM
analysis (ave. FC.1.3 and FDR,4%)
Found at: doi:10.1371/journal.pone.0001050.s004 (0.03 MB
XLS)
Table S4 Validation of signature genes charactering sub-types of
TAA using TaqManH real-time PCR assays. The signature genes
were originally identified by microarray using SAM analysis
(average fold change.1.3 and FDR,4%)
Found at: doi:10.1371/journal.pone.0001050.s005 (0.02 MB
DOC)
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